

CHAIR

**Beth Faiman, PhD,
MSN, APN-BC, AOCN,
BMTCN, FAAN, FAPO**

PeerView
Live

NCPD

Leading the Next Chapter of Myeloma Care

Oncology Nurse Stewardship in the Era of Innovative Antibodies and Cellular Therapies

 **Thursday, August 21, 2025**

 **6:30 PM - 7:30 PM ET**

 **Tubby's Tank House**

2909 River Dr
Thunderbolt, GA 31404

 **Beth Faiman, PhD, MSN, APN-BC, AOCN,
BMTCN, FAAN, FAPO**

Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio

Activity Description

Modern management of multiple myeloma (MM) has been transformed by advancements in three key therapeutic pathways: CD38-targeting platforms, BCMA-directed CAR-T therapies, and off-the-shelf immunotherapy options. CD38 antibody-based regimens, including novel quadruplet combinations, have become preferred frontline strategies. For relapsed/refractory disease, innovative treatments such as BCMA CAR-T cells, antibody-drug conjugates (ADCs), and bispecific antibodies are playing an increasingly critical role. The treatment landscape continues to evolve with the development of next-generation antibody and cellular therapies targeting novel antigens such as GPRC5D, offering new hope for durable remissions in patients across the disease spectrum.

In this series of PeerView community-based educational programs, presented in collaboration with the HealthTree Foundation for Multiple Myeloma and held at Oncology Nursing Society (ONS) chapter events, expert nurse faculty will provide guidance on optimizing the use of CD38-based regimens, BCMA CAR-T therapy, antibody-drug conjugates, and bispecific antibodies in various MM settings, while addressing core nursing practices such as administration, AE management, patient education, and referral for clinical trials. This initiative aims to empower oncology nurses to lead in delivering equitable, high-quality care to patients with MM across the treatment continuum.

Educational Objectives

Upon completion of this activity, participants should be better able to:

- Summarize the evidence supporting CD38 antibody-based platforms and BCMA and non-BCMA immunotherapies for the management of MM
- Educate patients with MM about treatment options, including benefits, risks, and participation in clinical trials, to support informed and shared decision-making
- Implement nurse-led approaches to manage treatment related adverse events and enhance patient outcomes
- Construct individualized care plans for MM patients to address therapy delivery considerations, such as dosing, long-term effects, patient monitoring, and psychosocial support needs

Accreditation, Support, and Credit



In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This educational activity is supported by independent medical education grants from AbbVie, GSK, and Johnson & Johnson.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.